An aggressive flu season in 2017 contributed to 145,000 global deaths, according to a recent study published by The Lancet. The high figure echoes early estimates of 80,000 flu deaths in the United States in the same year.

Although childhood cancer survival has improved markedly over the past few decades, a new study out of the Netherlands suggests a greater proportion of those survivors are at risk of developing heart failure at young ages, due in part to cardiotoxic treatments.

A railroad worker who survived an astonishing accident more than 170 years ago has gone on to become one of the more fascinating medical stories of all time, inspiring imaging research to this very day.

A recent op-ed published by Morning Consult urged Democrats in the House and Senate to permanently repeal the 2.3 percent medical device tax in order bring down healthcare costs and promote innovation.

A Florida-based surgeon must pay a $3,000 fine for removing a woman’s kidney because he thought it was a cancerous mass. The surgeon has pointed out that the patient's radiology results were not at the hospital at the time of the surgery.

Research published in Stroke Jan. 10 suggests clinicians overestimate the severity of intracerebral hemorrhage (ICH) and underestimate the severity of acute ischemic stroke (AIS), resulting in a bias that could influence patients’ outcomes and treatment plans.

AI may be better at spotting cervical cancer and precancer after a study found a deep learning algorithm was more accurate at recognizing the disease than human doctors.

GREENVILLE, N.C. — RFPi Inc. has received 510(k) clearance from the U.S. Food and Drug Administration to begin marketing for use by surgeons in open surgery its iCertainty™ blood flow and perfusion imaging medical device.

The Society of Breast Imaging (SBI) addressed the importance of diversity in breast imaging in a recent statement published online Jan. 9, stating that breast cancer does not affect all ethnic and socioeconomic populations equally.

RadioMedix and Curium announced that their diagnostic radiopharmaceutical, 64Cu-Dotatate, has received Fast Track designation from the FDA. 64Cu-Dotatate is a PET diagnostic agent being developed to detect neuroendocrine tumors.